Validation of Dyskinesia Rating Scales
MJFF Research Grant, 2009
Dyskinesias, or involuntary jerking movements, are troublesome problems for many Parkinson’s disease patients. Chemical studies have led to the development of several new treatment strategies. However, because dyskinesias are cause various degrees of difficulty for patients and are often perceived by patients and caregivers differently than by doctors, the rating of dyskinesias remains a scientific challenge. This program will examine a wide gamut of available rating scales to determine which one(s) detect change during dyskinesia treatment. Establishing excellent measurement tools of dyskinesias will allow future treatments to be evaluated in a uniform and maximally effective manner.
An international team of experts will test several dyskinesia scales in a group of Parkinson’s disease patients with dyskinesia. Patients will be treated with either amantadine or placebo (an inactive product). The study will be “blinded” so that the raters and the patients do not know if a given patient is receiving amantadine or placebo. Amantadine is selected for this trial, because it is the only drug that has received the designation of Efficacious for dyskinesia by the Movement Disorder Society. This conclusion was based however, on small studies and no large clinical trial of this drug has been conducted in dyskinetic patients. The scales will assess dyskinesia before and after several weeks of treatment.
Relevance to Diagnosis/Treatment of Parkinson’s Disease:
This study will establish a “gold standard” for rating dyskinesia in future trials of treatments in Parkinson’s disease patients. It will allow physicians to know the level of change that occurs with a standard and available treatment (amantadine) and to compare that level with changes that occur with newer treatments. Patients will benefit from this new international standard, because they can compare the likelihood and magnitude of anticipated improvement from different dyskinesia treatments, whether medical or surgical.
The anticipated outcomes of this study are:
• The impact of amantadine treatment on dyskinesia will be clearly defined.
• The effect of participation in a clinical program, even if no amantadine is given (“placebo improvements”), will be delineated.
• A hierarchy of numerous scales will be determined based on their absolute and relative capability to detect change during treatment.
• The best scale(s) to evaluate dyskinesia in clinical practice and research efforts will be identified.
INTERIM PROGRESS REPORT
This study is a multi-center investigation of the reliability and validity of numerous dyskinesia rating scales and is funded by The Michael J. Fox Foundation for Parkinson’s Research. There are eight centers enrolling subjects with Rush University Medical Center as the Organization Site. The eight study centers are University of Toronto, University of South Florida, Rush University Medical Center, Toulouse University, Oregon Health Sciences University, University of Alabama, Innsbruck Medical University and Duke University. We are close to enrolling our final subjects and when completed we will proceed with data analysis and dissemination of results.
Professor of Neurological Sciences and Pharmacology at Rush University Medical Center
Location: Chicago, Illinois
Professor at Rush University Medical Center
Location: Chicago, Illinois